FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792374303> ?p ?o ?g. }

• W2792374303 endingPage "15731" @default.
• W2792374303 startingPage "15721" @default.
• W2792374303 abstract "// Siobhan Conroy 1, 2 , Frank A.E. Kruyt 3 , Michiel Wagemakers 4 , Krishna P.L. Bhat 2, * and Wilfred F.A. den Dunnen 1, * 1 Department of Pathology and Medical Biology, Division of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 2 Department of Translational Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA 3 Department of Neurosurgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 4 Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands * These authors share senior authorship Correspondence to: Wilfred F.A. den Dunnen, email: w.f.a.den.dunnen@umcg.nl Keywords: glioblastoma; subclasses; angiogenesis; IL-8 Received: September 07, 2017      Accepted: February 10, 2018      Epub: February 28, 2018      Published: March 20, 2018 ABSTRACT Glioblastoma (GBM) is a highly aggressive brain tumor characterized by a high rate of vascularization. However, therapeutic targeting of the vasculature through anti-vascular endothelial growth factor (VEGF) treatment has been disappointing, for which Angiopoietin-2 (Ang-2) upregulation has partly been held accountable. In this study we therefore explored the interplay of Ang-2 and VEGFA and their effect on angiogenesis in GBM, especially in the context of molecular subclasses. In a large patient cohort we identified that especially combined high expression of Ang-2 and VEGFA predicted poor overall survival of GBM patients. The high expression of both factors was also associated with increased IL-8 expression in GBM tissues, but in vitro stimulation with Ang-2 and/or VEGFA did not indicate tumor or endothelial cell-specific IL-8 responses. Glioblastoma stem cells (GSCs) of the mesenchymal (MES) subtype showed dramatically higher expression of IL8 when compared to proneural (PN) GSCs. Secreted IL-8 derived from MES GSCs induced endothelial proliferation and tube formation, and the MES GBMs had increased counts of proliferating endothelial cells. Our results highlight a critical pro-angiogenic role of IL-8 in MES GBMs." @default.
• W2792374303 created "2018-03-29" @default.
• W2792374303 creator A5033051337 @default.
• W2792374303 creator A5042275454 @default.
• W2792374303 creator A5058229229 @default.
• W2792374303 creator A5058871373 @default.
• W2792374303 creator A5070213081 @default.
• W2792374303 date "2018-02-28" @default.
• W2792374303 modified "2023-10-16" @default.
• W2792374303 title "IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma" @default.
• W2792374303 cites W1540368941 @default.
• W2792374303 cites W1564674105 @default.
• W2792374303 cites W1604703931 @default.
• W2792374303 cites W1978041336 @default.
• W2792374303 cites W1985804036 @default.
• W2792374303 cites W1988692970 @default.
• W2792374303 cites W2001544973 @default.
• W2792374303 cites W2012255417 @default.
• W2792374303 cites W2024672608 @default.
• W2792374303 cites W2025183726 @default.
• W2792374303 cites W2027474877 @default.
• W2792374303 cites W2028380205 @default.
• W2792374303 cites W2034825883 @default.
• W2792374303 cites W2052804176 @default.
• W2792374303 cites W2053375897 @default.
• W2792374303 cites W2059614508 @default.
• W2792374303 cites W2059821930 @default.
• W2792374303 cites W2080184592 @default.
• W2792374303 cites W2080997194 @default.
• W2792374303 cites W2084170466 @default.
• W2792374303 cites W2085027690 @default.
• W2792374303 cites W2096287682 @default.
• W2792374303 cites W2106234246 @default.
• W2792374303 cites W2110265246 @default.
• W2792374303 cites W2110567472 @default.
• W2792374303 cites W2113942802 @default.
• W2792374303 cites W2124736921 @default.
• W2792374303 cites W2132697290 @default.
• W2792374303 cites W2145441158 @default.
• W2792374303 cites W2155892126 @default.
• W2792374303 cites W2156330848 @default.
• W2792374303 cites W2158681922 @default.
• W2792374303 cites W2161289668 @default.
• W2792374303 cites W2162518430 @default.
• W2792374303 cites W2164049072 @default.
• W2792374303 cites W2165238621 @default.
• W2792374303 cites W2165871546 @default.
• W2792374303 cites W2166215138 @default.
• W2792374303 cites W2167347313 @default.
• W2792374303 cites W2167650288 @default.
• W2792374303 cites W2170000965 @default.
• W2792374303 cites W2170367762 @default.
• W2792374303 cites W2261205543 @default.
• W2792374303 cites W2263421483 @default.
• W2792374303 cites W2280845138 @default.
• W2792374303 cites W2326749252 @default.
• W2792374303 cites W2328171087 @default.
• W2792374303 cites W2519556065 @default.
• W2792374303 doi "https://doi.org/10.18632/oncotarget.24595" @default.
• W2792374303 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5884659" @default.
• W2792374303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29644004" @default.
• W2792374303 hasPublicationYear "2018" @default.
• W2792374303 type Work @default.
• W2792374303 sameAs 2792374303 @default.
• W2792374303 citedByCount "27" @default.
• W2792374303 countsByYear W27923743032018 @default.
• W2792374303 countsByYear W27923743032019 @default.
• W2792374303 countsByYear W27923743032020 @default.
• W2792374303 countsByYear W27923743032021 @default.
• W2792374303 countsByYear W27923743032022 @default.
• W2792374303 countsByYear W27923743032023 @default.
• W2792374303 crossrefType "journal-article" @default.
• W2792374303 hasAuthorship W2792374303A5033051337 @default.
• W2792374303 hasAuthorship W2792374303A5042275454 @default.
• W2792374303 hasAuthorship W2792374303A5058229229 @default.
• W2792374303 hasAuthorship W2792374303A5058871373 @default.
• W2792374303 hasAuthorship W2792374303A5070213081 @default.
• W2792374303 hasBestOaLocation W27923743031 @default.
• W2792374303 hasConcept C126322002 @default.
• W2792374303 hasConcept C143998085 @default.
• W2792374303 hasConcept C151730666 @default.
• W2792374303 hasConcept C2776194525 @default.
• W2792374303 hasConcept C2776694085 @default.
• W2792374303 hasConcept C2777802072 @default.
• W2792374303 hasConcept C2779343474 @default.
• W2792374303 hasConcept C2780394083 @default.
• W2792374303 hasConcept C502942594 @default.
• W2792374303 hasConcept C71924100 @default.
• W2792374303 hasConcept C86803240 @default.
• W2792374303 hasConceptScore W2792374303C126322002 @default.
• W2792374303 hasConceptScore W2792374303C143998085 @default.
• W2792374303 hasConceptScore W2792374303C151730666 @default.
• W2792374303 hasConceptScore W2792374303C2776194525 @default.
• W2792374303 hasConceptScore W2792374303C2776694085 @default.
• W2792374303 hasConceptScore W2792374303C2777802072 @default.
• W2792374303 hasConceptScore W2792374303C2779343474 @default.
• W2792374303 hasConceptScore W2792374303C2780394083 @default.
• W2792374303 hasConceptScore W2792374303C502942594 @default.

• next